Author

Mikaela Bradley

Observed name: M B Bradley

Institutions: Beaumont Health, Beaumont Hospital, Royal Oak, Corewell Health William Beaumont University Hospital

Observed institutions: Memorial Sloan Kettering Cancer Center, Beaumont Health, Beaumont Hospital, Royal Oak, Corewell Health William Beaumont University Hospital

ORCID: 0000-0002-8425-2680

Observed ORCID: 0000-0002-8425-2680

OpenAlex ID: A5031629671

Highly polarized HLA class II antigen processing and presentation by human intestinal epithelial cells.

1998 · R M Hershberg, D H Cho, et al. · Journal of Clinical Investigation · 191

Phase II Multicenter, Open-Label Study of Oral ENMD-2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma

2020 · Ghassan K. Abou-Alfa, Robert Mayer, et al. · The Oncologist · 47

Genomic Characterization of ERBB2-Driven Biliary Cancer and a Case of Response to Ado-Trastuzumab Emtansine

2019 · Sebastian Mondaca, Pedram Razavi, et al. · JCO Precision Oncology · 41

Binimetinib plus Gemcitabine and Cisplatin Phase I/II Trial in Patients with Advanced Biliary Cancers

2018 · Maeve A. Lowery, Mikaela Bradley, et al. · Clinical Cancer Research · 35

A multicenter pilot study of nivolumab (NIVO) with drug eluting bead transarterial chemoembolization (deb-TACE) in patients (pts) with liver limited hepatocellular carcinoma (HCC).

2018 · James J. Harding, Joseph Patrick Erinjeri, et al. · Journal of Clinical Oncology · 14

A phase I/II trial of MEK162 in combination with gemcitabine (G) and cisplatin (C) for patients (pts) with untreated advanced biliary cancer (ABC).

2017 · Maeve Aine Lowery, Eileen Mary O'Reilly, et al. · Journal of Clinical Oncology · 6

A frequently occurring MSH2 variant in Iraqi and Chaldean patients with Lynch syndrome: evidence for a putative founder variant

2026 · Mikaela Bradley, Tara Rangarajan, et al. · Familial Cancer

Works count: 7

Citation count: 334

H-index: 6

I10-index: 5